Thyroid Cancer Pipeline Outlook 2025: Key Insights into Emerging Therapies and Companies

Strategic Insights -

The Thyroid Cancer pipeline landscape is becoming increasingly diverse, with over 50 active players working to develop more than 50 pipeline therapies for the treatment of Thyroid Cancer. Among the prominent companies emerging in this space are AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, and AstraZeneca. These companies are not only developing targeted therapies but are also exploring new combinations of existing treatments to tackle the complexities of Thyroid Cancer.

Key Takeaways:

  • On August 13, 2025, Novartis Pharmaceuticals announced a phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid cancer who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
  • Children's Hospital of Philadelphia conducted a study to evaluate the efficacy and safety of the combination of larotrectinib followed by 131I therapy for patients with NTRK fusion differentiated thyroid cancer.
  • DelveInsight's Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
  • Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, and Advenchen Laboratories.
  • Promising emerging drugs include rhTSH, Nivolumab, RX208, and AIC100.

Statistics:

  • Over 50+ companies are working on developing 51+ therapies for Thyroid Cancer treatment.
  • On August 13, 2025, 150 patients will be randomized to either dabrafenib plus trametinib or placebo.
  • The primary Phase II objective of the Children's Hospital of Philadelphia study is to evaluate the pulmonary structural response rate at 18 months to the combination of larotrectinib given for 6-months followed by 131I therapy.
  • The leading Thyroid Cancer Companies are investing heavily in the development of targeted therapies for the treatment of Thyroid Cancer.
  • The Thyroid Cancer pipeline landscape is becoming increasingly diverse, with over 50 active players working to develop more than 50 pipeline therapies for the treatment of Thyroid Cancer.

Sources:

  • DelveInsight's "Thyroid Cancer Pipeline Insight 2025" report (No publication date available)
  • Novartis Pharmaceuticals announcement (August 13, 2025)
  • Children's Hospital of Philadelphia study (August 13, 2025)
  • DelveInsight's Thyroid Cancer pipeline report (No publication date available)